Showing results (371-380 of 396) with videos related to
Sort By:
Pageof 40
Clinical Journal of the American Society of Nephrology : CJASN|May 14, 2021
Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1: A Placebo-Controlled Randomized Clinical TrialYaacov Frishberg, Georges Deschênes, Jaap W Groothoff, et al.The New England Journal of Medicine|February 10, 2025
Efficacy and Safety of Obinutuzumab in Active Lupus NephritisRichard A Furie, Brad H Rovin, Jay P Garg, et al.The New England Journal of Medicine|March 6, 2026
Efficacy and Safety of Obinutuzumab in Active Systemic Lupus ErythematosusRichard A Furie, Maria Dall'Era, Edward M Vital, et al.The New England Journal of Medicine|March 31, 2021
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1Sander F Garrelfs, Yaacov Frishberg, Sally A Hulton, et al.The New England Journal of Medicine|July 5, 2018
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin AmyloidosisDavid Adams, Alejandra Gonzalez-Duarte, William D O'Riordan, et al.The New England Journal of Medicine|October 27, 2023
Patisiran Treatment in Patients with Transthyretin Cardiac AmyloidosisMathew S Maurer, Parag Kale, Marianna Fontana, et al.Hypertension (Dallas, Tex. : 1979)|August 28, 2025
Overcoming Barriers to Developing and Implementing Novel Therapies for HypertensionKonstantin A Krychtiuk, Renato D Lopes, Victoria A Cargill, et al.The New England Journal of Medicine|August 30, 2024
Vutrisiran in Patients with Transthyretin Amyloidosis with CardiomyopathyMarianna Fontana, John L Berk, Julian D Gillmore, et al.Nature Genetics|February 16, 2010
A recurrent 16p12.1 microdeletion supports a two-hit model for severe developmental delaySanthosh Girirajan, Jill A Rosenfeld, Gregory M Cooper, et al.Physical Review Letters|February 6, 2025
Disentangling Centrality Bias and Final-State Effects in the Production of High-p_{T} Neutral Pions Using Direct Photon in d+Au Collisions at sqrt[s_{NN}]=200 GeVN J Abdulameer, U Acharya, C Aidala, et al.Pageof 40